The glucagon-like peptide-1 (GLP-1) agonist drugs have attractions as a treatment for type 2 diabetes since they positively alter a number of key pathophysiological defects. These include increasing insulin release, reducing glucagon release, slowing gastric emptying and reducing food intake. In numerous clinical trials these agents have been shown to reduce DCCT-aligned HbA 1c between 0.8% and 1.1% in patients with moderately controlled type 2 diabetes, whilst also being associated with some weight loss. Whilst medium-term safety and side-effect profiles are now well established, there are as yet no long-term studies on the safety of this group of drugs. The place of the GLP-1 agonists in the treatment paradigm for type 2 diabetes will evolve over the next decade.
Ahmad, S. and Swann, J. ( 2010) Exenatide and rare adverse events. N Engl J Med358: 1969-1972.
2.
Apovian, C.M., Bergenstal, R.M., Cuddihy, R.M., Qu, Y., Lenox, S., Lewis, M.S. et al. (2010) Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med123: 468.
3.
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M. et al. (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet374: 1606-1616.
4.
Bjerre Knudsen, L., Madsen, L.W., Andersen, S., Almholt, K., de Boer, A.S., Drucker, D.J. et al. (2010) Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation . Endocrinology151: 1473-1486.
5.
Brubaker, P.L.(2010) Minireview: update on incretin biology: focus on glucagon-like peptide-1 . Endocrinology151: 1984-1989.
6.
Buse, J.B., Henry, R.R., Han, J., Kim, D.D., Fineman, M.S. and Baron, A.D. ( 2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care27: 2628-2635.
7.
Buse, J.B., Rosenstock, J., Sesti, G., Schmidt, W.E., Montanya, E., Brett, J.H. et al. (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet374: 39-47.
8.
Butler, P.C., Dry, S. and Elashoff, R.(2010) GLP-1-based therapy for diabetes: what you do not know can hurt you . Diabetes Care33: 453-455.
9.
Chia, C.W., Carlson, O.D., Kim, W., Shin, Y.K., Charles, C.P., Kim, H.S. et al. (2009) Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes58: 1342-1349.
10.
DeFronzo, R.A. ( 2009) From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes58: 773-795.
11.
DeFronzo, R.A., Ratner, R.E., Han, J., Kim, D.D., Fineman, M.S. and Baron, A.D. ( 2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care28: 1092-1100.
12.
Drucker, D.J. ( 2006) The biology of incretin hormones. Cell Metabolism3: 153-165.
13.
Drucker, D.J., Sherman, S.I., Gorelick, F.S., Bergenstal, R.M., Sherwin, R.S. and Buse, J.B.(2010) Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care33: 428-433.
14.
Froud, T., Faradji, R.N., Pileggi, A., Messinger, S., Baidal, D.A., Ponte, G.M. et al. (2008) The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects . Transplantation86: 36-45.
15.
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P.A., Rodriguez-Pattzi, H., Olvera-Alvarez, I. et al. (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet373: 473-481.
16.
Heine, R.J., van Gaal, L.F., Johns, D., Mihm, M.J., Widel, M.H. and Brodows, R.G. ( 2005) Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Internal Med143: 559-569.
17.
Kendall, D.M., Riddle, M.C., Rosenstock, J., Zhuang, D., Kim, D.D., Fineman, M.S. et al. (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care28: 1083-1091.
18.
Kim, D., MacConell, L., Zhuang, D., Kothare, P.A., Trautmann, M., Fineman, M. et al. (2007) Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care30: 1487-1493.
19.
le Roux, C.W., Aylwin, S.J.B., Batterham, R.L., Borg, C.M., Coyle, F., Prasad, V. et al. (2006) Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters . Ann Surgery243: 108-114.
20.
Marre, M., Shaw, J., Brandle, M., Bebakar, W.M.W., Kamaruddin, N.A., Strand, J. et al. (2009) Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetic Med26: 268-278.
21.
Nauck, M., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A. et al. (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia50: 259-267.
22.
Nauck, M., Frid, A., Hermansen, K., Shah, N.S., Tankova, T., Mitha, I.H. et al. (2009a) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes . Diabetes Care32: 84-90.
23.
Nauck, M.A., Ratner, R.E., Kapitza, C., Berria, R., Boldrin, M. and Balena, R.(2009b) Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care32: 1237-1243.
24.
Parks, M. and Rosebraugh, C.(2010) Weighing risks and benefits of liraglutide-the FDA’s review of a new antidiabetic therapy. N Engl J Med362: 774-777.
25.
Pratley, R.E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S. et al. (2010) Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet375: 1447-1456.
26.
Rachman, J., Barrow, B.A., Levy, J.C. and Turner, R.C. ( 1997) Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia40: 205-211.
27.
Raman, V.S., Mason, K.J., Rodriguez, L.M., Hassan, K., Yu, X., Bomgaars, L. et al. (2010) The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care33: 1294-1296.
28.
Ratner, R.E., Maggs, D., Nielsen, L.L., Stonehouse, A.H., Poon, T., Zhang, B. et al. (2006) Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obesity Metab8: 419-428.
29.
Rosenstock, J., Klaff, L.J., Schwartz, S., Northrup, J., Holcombe, J.H., Wilhelm, K. et al. (2010) Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without prediabetes . Diabetes Care33: 1173-1175.
30.
Rosenstock, J., Reusch, J., Bush, M., Yang, F. and Stewart, M. ( 2009) Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes. Diabetes Care32: 1880-1886.
31.
Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B., Lalic, N., Antic, S. et al. (2009) Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia52: 2046-2055.
32.
Saliba, J., Wattacheril, J. and Abumrad, N.N.(2009) Endocrine and metabolic response to gastric bypass. Curr Opin Clin Nutrition Metab Care12: 1363-1950.
33.
Sjostrom, L., Lindroos, A.K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B. et al. (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med351: 2683-2693.
34.
Smith, U. and Gale, E.(2009) Does diabetes therapy influence the risk of cancer?Diabetologia52: 1699-1708.
35.
Sourij, H., Schmölzer, I., Kettler-Schmut, E., Eder, M., Pressl, H., deCampo, A. et al. (2009) Efficacy of a continuous GLP-1 infusion compared with a structured insulin infusion protocol to reach normoglycemia in nonfasted type 2 diabetic patients: a clinical pilot trial. Diabetes Care32: 1669-1671.
36.
Todd, J.F., Wilding, J.P.H., Edwards, C.M.B., Ghatei, M. and Bloom, S.R. ( 1997) Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. Eur J Clin Investigation27: 533-536.
37.
Toft-Nielsen, M.B., Madsbad, S. and Holst, J.J. ( 1999) Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care22: 1137-1143.
38.
US Food and Drug Administration (2010) FDA Website Memo, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022341s000TOC.cfm (accessed 25 January 2010).
39.
Vilsbøll, T., Krarup, T., Madsbad, S. and Holst, J.J. ( 2002) Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia45: 1111-1119.
40.
Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J.P. et al. (2007) Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care30: 1608-1610.
41.
Yoon, N., Cavaghan, M., Brunelle, R. and Roach, P.(2009) Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Therapeutics31: 1511-1523.
42.
Zander, M., Madsbad, S., Madsen, J.L. and Holst, J.J. ( 2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and [beta]-cell function in type 2 diabetes: a parallel-group study. Lancet359: 824-830.
43.
Zinman, B., Gerich, J., Buse, J.B., Lewin, A., Schwartz, S., Raskin, P. et al. (2009) Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care32: 1224-1230.
44.
Zinman, B., Hoogwerf, B.J., Garcia, S.D., Milton, D.R., Giaconia, J.M., Kim, D.D. et al. (2007) The effect of adding exenatide to a thiazolidindione in suboptimally controlled type 2 diabetes. Ann Intern Med146: 477-485.
